"Folate Receptor 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of GPI-anchored folate receptors that is expressed in tissues of epithelial origin. This protein is also identified as an ovarian-tumor-specific antigen.
| Descriptor ID |
D058975
|
| MeSH Number(s) |
D12.776.157.530.450.074.500.299.500.500 D12.776.395.550.448.370.500 D12.776.543.484.500.370.500 D12.776.543.550.418.370.500 D12.776.543.585.450.074.500.224.500.500 D12.776.543.750.301.500 D23.050.285.384
|
| Concept/Terms |
Folate Receptor 1- Folate Receptor 1
- Receptor 1, Folate
- Ovarian Tumor-Associated Antigen MOv18
- Ovarian Tumor Associated Antigen MOv18
- Folate Receptor alpha
- Receptor alpha, Folate
|
Below are MeSH descriptors whose meaning is more general than "Folate Receptor 1".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Carrier Proteins [D12.776.157]
- Membrane Transport Proteins [D12.776.157.530]
- Ion Pumps [D12.776.157.530.450]
- Anion Transport Proteins [D12.776.157.530.450.074]
- Organic Anion Transporters [D12.776.157.530.450.074.500]
- Folic Acid Transporters [D12.776.157.530.450.074.500.299]
- Folate Receptors, GPI-Anchored [D12.776.157.530.450.074.500.299.500]
- Folate Receptor 1 [D12.776.157.530.450.074.500.299.500.500]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- GPI-Linked Proteins [D12.776.395.550.448]
- Folate Receptors, GPI-Anchored [D12.776.395.550.448.370]
- Folate Receptor 1 [D12.776.395.550.448.370.500]
- Membrane Proteins [D12.776.543]
- Lipid-Linked Proteins [D12.776.543.484]
- GPI-Linked Proteins [D12.776.543.484.500]
- Folate Receptors, GPI-Anchored [D12.776.543.484.500.370]
- Folate Receptor 1 [D12.776.543.484.500.370.500]
- Membrane Glycoproteins [D12.776.543.550]
- GPI-Linked Proteins [D12.776.543.550.418]
- Folate Receptors, GPI-Anchored [D12.776.543.550.418.370]
- Folate Receptor 1 [D12.776.543.550.418.370.500]
- Membrane Transport Proteins [D12.776.543.585]
- Ion Pumps [D12.776.543.585.450]
- Anion Transport Proteins [D12.776.543.585.450.074]
- Organic Anion Transporters [D12.776.543.585.450.074.500]
- Folic Acid Transporters [D12.776.543.585.450.074.500.224]
- Folate Receptors, GPI-Anchored [D12.776.543.585.450.074.500.224.500]
- Folate Receptor 1 [D12.776.543.585.450.074.500.224.500.500]
- Receptors, Cell Surface [D12.776.543.750]
- Folate Receptors, GPI-Anchored [D12.776.543.750.301]
- Folate Receptor 1 [D12.776.543.750.301.500]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Neoplasm [D23.050.285]
- Folate Receptor 1 [D23.050.285.384]
Below are MeSH descriptors whose meaning is more specific than "Folate Receptor 1".
This graph shows the total number of publications written about "Folate Receptor 1" by people in this website by year, and whether "Folate Receptor 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Folate Receptor 1" by people in Profiles.
-
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.
-
Mirvetuximab soravtansine in folate receptor alpha (FRa)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1119-1125.
-
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int J Gynecol Cancer. 2024 Apr 01; 34(4):469-477.
-
Folate regulation of planar cell polarity pathway and F-actin through folate receptor alpha. FASEB J. 2024 01; 38(1):e23346.
-
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 05 01; 41(13):2436-2445.
-
CIC missense variants contribute to susceptibility for spina bifida. Hum Mutat. 2022 12; 43(12):2021-2032.
-
Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates. Nat Commun. 2021 09 13; 12(1):5410.
-
Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Bioorg Med Chem. 2021 02 15; 32:116013.
-
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs. 2021 04; 39(2):509-515.
-
CIC de novo loss of function variants contribute to cerebral folate deficiency by downregulating FOLR1 expression. J Med Genet. 2021 07; 58(7):484-494.